ArticleFrontiers in physiology2026
Integrated serum metabolomics reveals severity-associated exploratory metabolic signatures in burn patients.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically characterize the serum metabolome of burn patients using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Patients were stratified by burn severity based on total body surface area (TBSA; ≥30% vs. <30%). Exploratory metabolic signatures and candidate biomarkers associated with burn severity were investigated. Methods: Peripheral serum samples were collected from patients with TBSA ≥30% (n=33), TBSA <30% (n=28), and healthy controls (n=18). Serum metabolomic profiling was performed by UPLC-MS/MS. Principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were applied to identify differential metabolites. Pathway enrichment analysis was conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database via MetaboAnalyst. Receiver operating characteristic curve (ROC) analysis was performed to preliminarily evaluate the discriminatory performance of exploratory candidate biomarkers. Results: Distinct metabolic dysregulation was observed between burn severity groups. Compared with the healthy control group, twenty-three significantly altered metabolites were identified in patients with TBSA ≥30%, while thirty-one metabolites were altered in patients with TBSA <30%. Severe burns (TBSA ≥30%) predominantly disrupted amino acid and glycerophospholipid metabolism, whereas moderate burns (<30%) mainly involved lipid-related pathways. Patients with TBSA ≥30% exhibited perturbations across a broader range of metabolic pathways. ROC analysis identified nine exploratory candidate biomarkers (area under the curve [AUC] >0.8) in patients with TBSA ≥30% and eight in patients with TBSA <30%, suggesting preliminary discriminatory potential within the current cohort for distinguishing metabolic alterations associated with different burn severities. Conclusion: Burn severity may be associated with distinct serum metabolomic signatures. Key pathways and exploratory candidate biomarkers associated with burn severity-related metabolic alterations were identified. These findings provide a metabolomics-based reference framework for future studies investigating burn severity-associated metabolic alterations and may support future mechanistic and translational research in burn care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.